GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nuwellis Inc (NAS:NUWE) » Definitions » Return-on-Tangible-Asset

Nuwellis (Nuwellis) Return-on-Tangible-Asset : -210.81% (As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Nuwellis Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Nuwellis's annualized Net Income for the quarter that ended in Mar. 2024 was $-17.32 Mil. Nuwellis's average total tangible assets for the quarter that ended in Mar. 2024 was $8.22 Mil. Therefore, Nuwellis's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -210.81%.

The historical rank and industry rank for Nuwellis's Return-on-Tangible-Asset or its related term are showing as below:

NUWE' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -251.97   Med: -116.25   Max: -52.73
Current: -145.84

During the past 13 years, Nuwellis's highest Return-on-Tangible-Asset was -52.73%. The lowest was -251.97%. And the median was -116.25%.

NUWE's Return-on-Tangible-Asset is ranked worse than
91.8% of 866 companies
in the Medical Devices & Instruments industry
Industry Median: -2.745 vs NUWE: -145.84

Nuwellis Return-on-Tangible-Asset Historical Data

The historical data trend for Nuwellis's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuwellis Return-on-Tangible-Asset Chart

Nuwellis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -251.97 -123.65 -77.55 -52.73 -117.35

Nuwellis Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -120.23 -113.89 -99.91 -207.87 -210.81

Competitive Comparison of Nuwellis's Return-on-Tangible-Asset

For the Medical Devices subindustry, Nuwellis's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nuwellis's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nuwellis's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Nuwellis's Return-on-Tangible-Asset falls into.



Nuwellis Return-on-Tangible-Asset Calculation

Nuwellis's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-20.209/( (24.673+9.77)/ 2 )
=-20.209/17.2215
=-117.35 %

Nuwellis's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-17.32/( (9.77+6.662)/ 2 )
=-17.32/8.216
=-210.81 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Nuwellis  (NAS:NUWE) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Nuwellis Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Nuwellis's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Nuwellis (Nuwellis) Business Description

Traded in Other Exchanges
Address
12988 Valley View Road, Eden Prairie, MN, USA, 55344
Nuwellis Inc is a medical device company. Its solutions include Aquadex Smartflow System and RenalSense Clarity RMS. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Clarity RMS is a kidney monitoring system that continuously measures urine output and flows, automatically displaying real-time data to the medical staff.
Executives
David Mcdonald director 6 KEMPTON PLACE, #12, SARATOGA SPRINGS NY 12866
Archelle Georgiou Feldshon director 1420 SHORELINE DRIVE, WAYZATA MN 55391
Robert Benjamin Scott officer: Chief Financial Officer 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Michael Kendrick Mccormick director 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Gregory D Waller director 1717 W COLLINS AVENUE, ORANGE CA 92867
Jon W Salveson director 800 NICOLLET MALL, MINNEAPOLIS MN 55402
Nestor Jr. Jaramillo officer: Chief Commercial Officer 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Lynn Larson Blake officer: Chief Financial Officer 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
George Montague officer: CFO and Treasurer 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Neil P Ayotte officer: SVP, Secretary, GC & CCO 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Paul Wotta officer: Principal Accounting Officer 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Claudia Drayton officer: Chief Financial Officer 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Thomas P. Lynch officer: Chief Legal/Compliance Officer 3344 N. TORREY PINES COURT, LA JOLLA CA 92037
Steven Frank Brandt director 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Maria Rosa Costanzo director 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344